SpringWorks Therapeutics, Inc.: Goldman Sachs continues to buy







Marketzone with MT Newswires 2022

All the news about SPRINGWORKS THERAPEUTICS, INC.
08/05SPRINGWORKS THERAPEUTICS, INC. : Goldman Sachs continues to buy

ZM

08/04SpringWorks Therapeutics, Inc. announces its results for the second quarter and the..

THIS

07/15SpringWorks Therapeutics, Inc. Appoints Carlos Albán to Board of Directors

THIS

07/15SpringWorks Therapeutics, Inc. announces the resignation of Stephen Squinto as member..

THIS

06/13SPRINGWORKS THERAPEUTICS, INC. : Wedbush still for purchase

ZM

06/06SPRINGWORKS THERAPEUTICS, INC. : HC Wainwright maintains its Buy recommendation

ZM

05/27SpringWorks Therapeutics shares tumble after lowering target price..

MT

05/27SPRINGWORKS THERAPEUTICS, INC. : Wedbush favorable on the file

ZM

05/24SPRINGWORKS THERAPEUTICS, INC. : Goldman Sachs continues to buy

ZM

05/24SpringWorks Therapeutics, Inc. announces positive results from the DeFi trial, a..

THIS

Analyst Recommendations for SPRINGWORKS THERAPEUTICS, INC.

2022 turnover –
–
–
2022 net result -277M
–
-272M
trso. net 2022 43.1M
–
42.4M
PER 2022-6.82x
2022 return–
Capitalization 1,684M
1,684M
1,658M
VE / CA 2022–
VE / CA 202349.8x
Number of employees190
Floating81.4%

Chart SPRINGWORKS THERAPEUTICS, INC.


Hard :

Period:




SpringWorks Therapeutics, Inc.: Chart Technical Analysis SpringWorks Therapeutics, Inc. | Market area

Trending Technical Analysis SPRINGWORKS THERAPEUTICS, INC.

Short termMiddle termLong term
TrendsbullishNeutralBearish

Evolution of the Income Statement

Sale

Purchase

Average recommendationTO BUY
Number of Analysts6
Last Closing Price$36.86
Average price target$80.40
Deviation / Average Target118%

Officers and Directors




Source link -88